Literature DB >> 21244730

Aberrant mucin glycoprotein patterns of chronic rhinosinusitis patients with bacterial biofilms.

Lorwai Tan1, Alkis Psaltis, Leonie M Baker, Mike McGuckin, Karine Rousseau, Peter-John Wormald.   

Abstract

BACKGROUND: Increasingly bacterial biofilms have been implicated in chronic rhinosinusitis (CRS), and conventional treatment methods have failed to completely eradicate biofilms. (1) Terminal sialic acids present on sinus mucosal glycoproteins are targets for bacterial adherence and biofilm formation. (2) A subpopulation of CRS patients is more susceptible to biofilm formation due to aberrant terminal sialic residue distribution patterns of glycoproteins on their mucosa. (3) The higher levels of sialyl transferase (ST)6Gal1 gene expression contribute to the overall aberrant glycosylation patterns on the host mucosa that predispose this patient cohort to developing biofilms. (4) Mucin glycoprotein MUC7 that has known bactericidal activity displays an overall reduced terminal sugar profile in biofilm positive CRS patients.
METHODS: Confocal scanning laser microscopy, glycoarray analysis, real-time polymerase chain reaction of ST6Gal1, neuraminidase assays and multivariate analysis were used to compare production of sialic acid-degrading enzymes in sinus biopsies from biofilm positive and negative CRS patients with mucosa from healthy controls.
RESULTS: Biofilm-positive CRS patients expressed aberrant glycoprotein patterns with terminal sialics of between 70 and 90 kD (stress value = 0.1414). The ST6Gal1 gene was upregulated, and bacteria isolated from these patients exhibit significantly higher neuraminidase activity (p = 0.0343). We detected a significant lack in the overall expression of terminal sugar residues of MUC7 (stress value = 0.088).
CONCLUSIONS: We observed a strong positive correlation between the aberrant terminal sugar patterns in this sub group of CRS patients with biofilms. The innate immunity function of their MUC7 glycoprotein against bacterial invasion may be compromised in CRS patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21244730     DOI: 10.2500/ajra.2010.24.3504

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  7 in total

1.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

Authors:  Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2013-08-14       Impact factor: 3.467

2.  Enhanced expressions of lysozyme, SLPI and glycoprotein 340 in biofilm-associated chronic rhinosinusitis.

Authors:  Dong Dong; Zhao Yulin; Xie Yan; Zhang Hongyan; Zhang Shitao; Wang Jia
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06       Impact factor: 2.503

Review 3.  Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.

Authors:  William J Janssen; Adrianne L Stefanski; Bruce S Bochner; Christopher M Evans
Journal:  Eur Respir J       Date:  2016-09-01       Impact factor: 16.671

4.  Microbiome complexity and Staphylococcus aureus in chronic rhinosinusitis.

Authors:  Leah M Feazel; Charles E Robertson; Vijay R Ramakrishnan; Daniel N Frank
Journal:  Laryngoscope       Date:  2012-01-17       Impact factor: 3.325

Review 5.  Role of bacterial and fungal biofilms in chronic rhinosinusitis.

Authors:  Andrew Foreman; Sam Boase; Alkis Psaltis; Peter-John Wormald
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 6.  Biofilms in chronic rhinosinusitis: Pathophysiology and therapeutic strategies.

Authors:  Judd H Fastenberg; Wayne D Hsueh; Ali Mustafa; Nadeem A Akbar; Waleed M Abuzeid
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2016-05-05

Review 7.  Microbiota Composition and the Integration of Exogenous and Endogenous Signals in Reactive Nasal Inflammation.

Authors:  Francesco Antonio Salzano; Luigi Marino; Giovanni Salzano; Riccardo Maria Botta; Giovanni Cascone; Umberto D'Agostino Fiorenza; Carmine Selleri; Vincenzo Casolaro
Journal:  J Immunol Res       Date:  2018-06-03       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.